Cosan confirmed to the market that it has resumed negotiations to sell part of its stake in Rumo (RAIL3) and did not rule out changing the rule that currently blocks a large investor from taking a major position in the railway. For CSAN3 shareholders, this reopens the primary escape hatch for the holding company's debt, though there is still no agreed price, no buyer, and no signed contract.
What Happened to CSAN3 and Rumo?
In a filing on November 11, Cosan stated that it is holding discussions regarding a potential partial sale of its stake in Rumo and remains open to evaluating different alternatives and structures for the transaction. The statement was issued in response to a report by Brazil Journal indicating that Cosan is analyzing the removal of Rumo's 15% poison pill as part of talks with strategic investors. The holding company did not confirm that it will eliminate the ownership cap. It stated only that any rule change must follow applicable corporate procedures, including approval by Rumo shareholders at a special general meeting.
Before the filing, the media report had already moved the stock price. Cosan shares closed up 12.69% at R$ 3.02, while Rumo shares climbed 7.95% to R$ 16.02. The following day, after the company tempered expectations, CSAN3 shares pulled back 5.61% on Thursday (November 12). By our math, this leaves the stock near R$ 2.85, still above the R$ 2.80 level seen on Monday (November 9).
To date, nothing has been sold. The company confirmed that it is in talks and does not rule out changing the cap. To understand why the market reacted so strongly, it helps to examine what that restriction prevents.
What Is Rumo's Poison Pill and Why Does It Complicate the Sale?
The poison pill is a corporate bylaws clause that requires any investor reaching a 15% stake in Rumo to launch a tender offer for 100% of the company's capital. For anyone looking to buy just a significant minority slice, this drastically increases the cost of the deal. According to Brazil Journal, removing the provision would allow a major investor to build a position in the company without needing to extend an offer to all market shareholders.
This is the aspect that interests Cosan: a broader field of potential buyers tends to improve the price. The news is less favorable for pure-play RAIL3 shareholders. The cap also protects minority investors in the railway, because without it, a large buyer does not have to extend an offer to all unitholders. That is why the Rumo shareholder meeting is unlikely to be a mere formality.
And why believe the deal now, when the exact same sale fell through a month ago?
Didn't This Sale Fall Through in October?
It did. On October 20, Cosan announced that exclusivity talks with interested parties had ended without an agreement, as we covered in our analysis of the end of the Rumo talks. According to Brazil Journal, Grupo Mexico and a consortium formed by Chinese trading house COFCO and Bunge negotiated with Cosan to buy up to 15% of Rumo, but the parties failed to reach a deal. The publication also reported that conversations resumed following the second-round election.
What stalled the deal previously was valuation. According to press reports in October, some proposals received earlier valued the stake at roughly 30% below Rumo's market price. The macroeconomic backdrop has also shifted: before the second-round vote, Rumo shares traded above R$ 19, dropped to R$ 14 following Lula's victory, and have since recovered to hover near R$ 16. With the railway trading lower on the exchange, waiting for a better price became more costly for Cosan. This helps explain the return to the negotiating table and the willingness to open up the bidding process. That leaves the crucial question: how much cash would actually come in?
How Much Would Cosan Raise and How Much Debt Would It Clear?
No financial figures were disclosed. However, we can run the numbers using public data. In August, Citi calculated that selling roughly a 15% stake in Rumo for approximately R$ 5 billion would support the holding company's deleveraging thesis and could also cut Cosan's financial expenses by about R$ 0.8 billion per year. For comparison, all of Cosan is valued at roughly R$ 12 billion on the stock exchange.
We recalculated the figures at today's prices. Cosan holds 377.8 million shares of Rumo, equivalent to 20.33% of its capital, out of roughly 1.86 billion total shares. Therefore, a 15% stake in the railway represents about 279 million shares. The three scenarios below are our own estimates:
Strategic buyer pays above market, as in the August valuation
279 million shares × R$ 16.02
Mirrors the proposals Cosan rejected in October
The difference between the best and worst-case scenarios is nearly R$ 2 billion. For a holding company that, by our metrics, carries a net debt-to-EBITDA ratio of 8.54x (compared to a five-year median of 3.65x) and whose operating income covers interest expense by just 0.20x, this is a significant variance. The estimated R$ 0.8 billion in annual interest savings calculated by Citi equals roughly R$ 0.20 per share per year (our calculation based on about 3.97 billion shares). That is money currently flowing to banks rather than turning into returns for shareholders.
The news is positive, but it remains strictly a possibility. Rumo is the most valuable and most liquid asset in Cosan's portfolio. A partner willing to pay close to market price would pull the holding company out of its stress zone faster than any other exit strategy. Do not expect a dividend from this sale, however: Cosan has not paid a dividend since its June 6, 2024 ex-date (R$ 0.4515 per share) and is coming off a net loss. The proceeds would go toward debt reduction. For the investor, any gains would come from stock appreciation driven by debt relief, not a cash payout.
Why Did the Stock Surge and Then Drop?
Because the market priced in the most optimistic scenario (the ownership cap removed, competing buyers, and a full valuation) before the company made any official statements. The evening filing confirmed the negotiations but pushed any change to the cap onto a shareholder meeting that has not even been called yet. This mirrors the pattern seen with Compass two days prior: the press reports a potential sale, and the holding company confirms there is interest without anything being signed, as we detailed in Cosan's response to B3 regarding Compass.
The stock is exceptionally sensitive to these headlines because the market values the holding company primarily as the sum of its parts minus its debt. When the share price drops as sharply as it has over the past 12 months (−54%), any sign of incoming cash moves the stock by double digits in either direction. UBS-BB, which upgraded Cosan to a buy with a price target of R$ 4.70, had already factored in asset sales. This week's news makes that outcome slightly more probable, but far from guaranteed.
What Needs to Happen for the Investment Thesis to Play Out?
A summary of the current setup:
- The company confirmed in writing that it is in negotiations, moving beyond anonymous sources; this represents the asset sale with the clearest market valuation.
- Modifying the poison pill broadens the list of potential buyers; removing it could also bring another strategic player back to the table—Ultrapar.
- Citi estimated annual financial expense cuts of R$ 0.8 billion, offering direct relief to the income statement line item that weighs most heavily on results.
- A deal already fell through in October for the same reason as always: inadequate offered pricing.
- Any change to the ownership restriction depends on a Rumo shareholder meeting, where minority railway investors have strong incentives to resist.
- Even in the best-case scenario, the sale covers only part of the debt, and Raízen remains a source of pressure (see the agreement that eliminated Raízen's tax contingencies).
The next concrete signal will be the call for a Rumo shareholder meeting to address the poison pill. If that meeting is scheduled, it indicates advanced negotiations. Until then, CSAN3 will continue trading at the mercy of headlines.
